Form 8-K - Current report:
SEC Accession No. 0001193125-25-132890
Filing Date
2025-06-02
Accepted
2025-06-02 09:31:48
Documents
12
Period of Report
2025-06-02
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d949267d8k.htm   iXBRL 8-K 38252
  Complete submission text file 0001193125-25-132890.txt   155131

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA trvi-20250602.xsd EX-101.SCH 2880
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20250602_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20250602_pre.xml EX-101.PRE 11281
14 EXTRACTED XBRL INSTANCE DOCUMENT d949267d8k_htm.xml XML 3639
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 251013317
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)